Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zhejiang Medicine Co. Ltd.

www.china-zmc.com/index_en.asp

Latest From Zhejiang Medicine Co. Ltd.

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?

With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.

BioPharmaceutical Cancer

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A

FDA GMP Warning Letters Review: API Supplier Warnings Surge On Data Integrity Concerns

US FDA’s drug GMP warning letters to API suppliers tripled in 2016, driven by data integrity findings in China and India and concerns about facilities and equipment maintenance. Trend could spell trouble for commercial production and launches. While there’s no turning back the clock on supply chain globalization, there’s no turning back the clock on FDA warning letters either.

Manufacturing Quality

WuXi Biologics Readies For Hong Kong IPO

As predicted by Scrip last July, WuXi AppTec has moved one step closer to spinning out its biologics unit through an IPO on the Hong Kong equity market, while its main business unit is also proceeding with plans for a China domestic relisting.

China Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Nutraceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Zhejiang Medicine Co. Ltd.
  • Senior Management
  • Chun Feng Li, CFO
    Xiao Yue Jiang, Acting General Mgr.
  • Contact Info
  • Zhejiang Medicine Co. Ltd.
    Phone: 571 8721 3883
    No. 268 Dengyun Rd.
    Gongshu Dist.
    Hangzhou, 310011
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register